Piper Sandler analyst Adam Maeder lowered the firm’s price target on ShockWave Medical to $280 from $300 and keeps an Overweight rating on the shares. The analyst updated models in medical technology and devices to reflect recent company updates.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SWAV:
- ShockWave Medical to acquire Neovasc for $27.25 per share
- ShockWave Medical sees 2023 revenue $660M-$680M, consensus $639.85M
- ShockWave Medical sees 2022 revenue $489M-$490M, consensus $487.2M
- Shockwave Medical Announces Agreement to Acquire Neovasc
- ShockWave Medical sees Q4 revenue $143M-$144M, consensus $141.5M